Appili Therapeutics advances late-stage study of favipiravir for COVID-19

 

• Dosing is underway in a Phase 3 clinical trial, PRESECO, evaluating Appili Therapeutics' (OTCQX:APLIF) Avigen tablets (favipiravir) for the treatment of COVID-19 patients with mild-to-moderate symptoms. The goal is to alleviate the symptoms and prevent disease progression.
• Enrollment target is ~826 subjects. The primary endpoint is time to sustained recovery from day 0 to day 21 compared to placebo.
• Preliminary data should be available in H1 2021.
• Favipiravir is a broad-spectrum antiviral developed by FUJIFILM Toyama Chemical Co., Ltd. (OTCPK:FUJIF). It is approved in Japan for the treatment of influenza. Based on encouraging clinical data, Russia and India recently approved its emergency use for COVID-19. FUJIFILM recently announced positive results from a Phase 3 study in hospitalized COVID-19 patients.
• Appili is part of a consortium that includes Dr. Reddy's Laboratories (NYSE:RDY), Global Response Aid and FUJIFILM backing global development and distribution (ex. Japan, China and Russia) of Avigan tablets for the potential treatment and prevention of COVID-19.
• https://seekingalpha.com/news/3640768-appili-therapeutics-advances-late-stage-study-of-favipiravir-for-covidminus-19